Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.64 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MGAM | O43451 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5682764 | 1.00 | SRD5A2 (0.64) | SRD5A2SRD5A1NR3C1SHBGPGR | |
| SCHEMBL4269548 | 1.00 | SRD5A2 (0.64) | SRD5A2SRD5A1NR3C1SHBGPGR | |
| SCHEMBL4278292 | 1.00 | SRD5A2 (0.64) | SRD5A2SRD5A1NR3C1SHBGPGR | |
| SCHEMBL13843998 | 0.85 | SRD5A1 (0.65) | SRD5A2SRD5A1AR | |
| SCHEMBL9546858 | 0.85 | SRD5A1 (0.65) | SRD5A2SRD5A1AR | |
| SCHEMBL8064151 | 0.84 | SRD5A1 (0.67) | SRD5A2SRD5A1AR | |
| SCHEMBL8064153 | 0.84 | SRD5A1 (0.67) | SRD5A2SRD5A1AR | |
| SCHEMBL13844000 | 0.83 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL5907001 | 0.83 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL14477862 | 0.83 | SRD5A2 (0.73) | SRD5A2SRD5A1ARGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605152-B2 | 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605152-B2 | 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1467739-A4 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | disclosed |
| EP-1467739-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059293-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-0880540-B1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | AVENTIS PHARMA INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6365597-B1 | FOR THERAPY OF ANDROGEN AND ESTROGEN MEDIATED DISORDERS, INCLUDING BENIGN PROSTATIC HYPERPLASIA, ANDROGEN MEDIATED PROSTATE CANCER, ESTROGEN MEDIATED BREAST CANCER AND ACNE | AVENTIS PHARMACEUTICALS INC. | 2002-04-02 | — | — | US | disclosed |
| EP-0641204-B1 | 17-ETHERS AND THIOETHERS OF 4-AZA-STEROIDS | MERCK & CO INC (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-0880540-A1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | HOECHST MARION ROUSSEL, INC. (US) | 1998-12-02 | — | — | EP | disclosed |
| US-5693809-A | PREGNANES FOR TREATING ALOPECIA, ACNE AND SKIN DISORDER | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| WO-1997030069-A1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| US-5536727-A | TREATMENT OF HYPERANDROGENIC DISEASES | MERCK & CO., INC. (US) | 1996-07-16 | — | — | US | disclosed |
| EP-0641204-A4 | 17-ETHERS AND THIOETHERS OF 4-AZA-STEROIDS. | MERCK & CO INC (US) | 1995-08-23 | — | — | EP | disclosed |
| EP-0641204-A1 | 17-ETHERS AND THIOETHERS OF 4-AZA-STEROIDS | MERCK & CO. INC. (US) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | SHBG, CYP19A1, NR5A1 | SRD5A2 11/4885SRD5A1 5/4885NR3C1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.